News | April 01, 2009

Medtronic Announces International Market Release of Driver Sprint RX Coronary Stent System

April 1, 2009 - Medtronic Inc. this week began the international launch of the Driver Sprint RX Coronary Stent System, which received the CE Mark in February and is planned to be commercially available in more than 100 countries worldwide.

“The Driver stent system has always been very deliverable,” explained Dr. C. Dubois of Leuven University Hospital in Belgium. “Now, the new Driver Sprint system makes it even more deliverable for the most challenging anatomy.”

The new system combines the Driver Bare-Metal Stent (BMS) with an improved delivery system. Specifically, it incorporates a new tip design for a low profile and an enhanced shaft design, which together greatly improve the device’s deliverability, the company said. These innovations are also incorporated in Medtronic’s Endeavor Sprint and Resolute drug-eluting stent systems.

The Driver BMS has a unique modular construction and ultra-thin, round, edgeless struts allow for smooth delivery. This design also provides excellent radial strength and high conformability to the vessel wall. Medtronic said more than 2 million Driver stents have been implanted worldwide since 2002 when the platform was first introduced for clinical studies.

The outcomes of more than 3,400 patients followed in both registries and randomized controlled trials have demonstrated the device’s clinical efficacy. Short-term target lesion revascularization (TLR) rates for Driver patients in registries are low, ranging from 3.4 – 9.4 percent at six months and from 6.7 – 7 percent at nine months. In addition, nearly 600 Driver patients were followed to four years in ENDEAVOR II, and five-year data from this trial is due for release at EuroPCR in May. The TLR rate for these Driver patients (n=599) at four years is low for a BMS at 15.8 percent.

For more information: www.driverstent.com, www.medtronic.com

Related Content

Biotronik, PRO-Kinetic Energy cobalt chromium coronary stent system, FDA approval
Technology | Stents Bare Metal| February 15, 2017
The PRO-Kinetic Energy Cobalt Chromium (CoCr) Coronary Stent System from Biotronik has gained U.S. Food and Drug...
Biotronik Astron stent
Technology | Stents Peripheral| December 31, 2015
December 31, 2015 - The U.S.
Technology | Stents Bare Metal| December 09, 2015
Medinol U.S. recently opened their commercial business in Parsippany, New Jersey, followed by the launch of the...
News | Antiplatelet and Anticoagulation Therapies| June 11, 2015
Patients who received a bare metal coronary stent did not display significant differences in rates of adverse events...
Technology | July 22, 2014
July 22, 2014 — Boston Scientific announced it received U.S. Food and Drug Administration (FDA) approval for the Rebel...
Boston Scientific Rebel Platinum Chromium Coronary Stent System Bare Metal
News | March 13, 2014
Boston Scientific Corp. received CE marking for the Rebel Platinum Chromium Coronary Stent System, the company's latest...
Biosensors BioMatrix

The LEADERS Trial showed that the Biosensors BioMatrix, a drug-eluting stent with a biodegradable abluminal polymer coating, was functionally equivalent to a regular nonbiodegradable stent.

Feature | February 04, 2013 | Kamran Zamanian, Ph.D.
The interventional cardiology market includes, but is not limited to, drug-eluting stents, bare-metal stents,...
News | December 27, 2012
December 27, 2012 — Biotronik announced that the first implant has taken place in the BIOHELIX-I trial in the United...
Overlay Init